Biohaven BHVN Business Segments — R&D Share-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biohaven in its filing.
Tagged under the XBRL concept bhvn:ResearchAndDevelopmentExpenseShareBasedCompensationExpense.
The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biohaven's business segments — r&d share-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biohaven's business segments — R&D share-based compensation expense?
- Biohaven (BHVN) reported business segments — R&D share-based compensation expense of $18.48M in Q1 2026.
- How has Biohaven's business segments — R&D share-based compensation expense changed year-over-year?
- Biohaven's business segments — R&D share-based compensation expense decreased by 47.6% year-over-year, from $35.23M to $18.48M.
- What is the long-term trend for Biohaven's business segments — R&D share-based compensation expense?
- Over 3 years (2022 to 2025), Biohaven's business segments — R&D share-based compensation expense has grown at a -14.5% compound annual growth rate (CAGR), from $116.38M to $72.79M.
- What does business segments — R&D share-based compensation expense mean?
- Represents the non-cash expense associated with equity-based awards granted to research and development staff. This metric highlights the cost of aligning employee incentives with long-term shareholder value within the R&D function. It is essential for understanding the total compensation structure and potential dilution effects.